Download our latest Case Study: Exploitant services for MAA product You will learn more about: ▪ Exploitant status in France ▪ Exploitant services ▪ Pharmablue our Exploitant establishement

An American pharmaceutical company starting to build its European affiliates entrusted PharmaBlue with the responsibility of submitting, obtaining, and implementing a French Early Access Program for its orphan drug. PharmaBlue support them for the whole process of submission (advice, writing…

Download the 5 common mistakes companies face when navigating French Early Access Programs: Planning from the early stage Not enough European/French resources available Partner with a "low-cost" Exploitant Early Access Programs - Differences in Regulation and Implementation Changing regulations that…

You are not familiar with the fast evolving Early Access French regulation and Exploitant Status ? Download the list of requirements for the Early Access program.

Our experts at BlueReg are covering the Early Access Programs specific to France (ATU), and how to take advantage of it. The different subjects discussed in the webinar are : Why Early Access (ATU) for new innovative drugs in France…